Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A cost-effectiveness clinical decision analysis model for schizophrenia.

C S Palmer1, D A Revicki, L A Genduso

  • 1MEDTAP International, Inc., Bethesda, MD, USA.

The American Journal of Managed Care
|February 6, 1998
PubMed
Summary

Olanzapine is a more cost-effective antipsychotic treatment for schizophrenia than haloperidol or risperidone, offering better outcomes and fewer relapses over five years.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument.

PharmacoEconomics - open·2023
Same author

The content validity of the PSS in patients with plaque psoriasis.

Journal of patient-reported outcomes·2018
Same author

Revised Functional Capacity Index as a predictor of outcome following injury.

The British journal of surgery·2017
Same author

The full spectrum of handlebar injuries in children: a decade of experience.

Injury·2013
Same author

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.

The British journal of dermatology·2013
Same author

Epidemiological burden of minor, major and fatal trauma in a national injury pyramid (Br J Surg 2012; 99(Suppl 1): 114-121).

The British journal of surgery·2012

Area of Science:

  • Pharmacoeconomics
  • Psychiatry
  • Health Outcomes Research

Background:

  • Schizophrenia treatment involves significant medical costs and varied effectiveness.
  • Estimating long-term cost-effectiveness of antipsychotics is crucial for clinical decision-making.

Purpose of the Study:

  • To compare the 5-year cost-effectiveness of olanzapine, haloperidol, and risperidone for schizophrenia.
  • To evaluate treatment outcomes including disability-free days and relapse rates.

Main Methods:

  • A decision analytic Markov model was employed.
  • Model parameters were derived from clinical trials, literature, and expert judgment.
  • Direct medical costs and effectiveness indicators (Brief Psychiatric Rating Scale, quality-adjusted life years, relapse) were analyzed.

Related Experiment Videos

Main Results:

  • Olanzapine therapy resulted in more disability-free time and fewer relapses compared to haloperidol and risperidone over 5 years.
  • Olanzapine was associated with lower 5-year medical costs than both haloperidol and risperidone.
  • Sensitivity analyses confirmed olanzapine's cost-effectiveness and superior outcomes.

Conclusions:

  • Olanzapine demonstrates superior cost-effectiveness and effectiveness compared to haloperidol and risperidone for schizophrenia treatment.
  • The findings support olanzapine as a preferred treatment option based on economic and clinical outcomes.